Document is current
Any future updates will be listed below
-
Authors
Trentzsch, Katrin https://orcid.org/0000-0003-2832-4640
Schriefer, Dirk https://orcid.org/0000-0002-7524-7628
Stölzer-Hutsch, Heidi https://orcid.org/0000-0002-1656-501X
Inojosa, Hernan https://orcid.org/0000-0002-1377-836X
Ziemssen, Tjalf https://orcid.org/0000-0001-8799-8202
-
Funding
Funding for this research was provided by:
Technische Universität Dresden
- License Information
-
More Information
Article History
Received: 10 June 2025
Accepted: 9 September 2025
First Online: 17 September 2025
Declarations
:
: K.T., D.S. and H.SH declare no competing interests. H.I. received speaker honoraria from Roche and financial support for research activities from Teva, Biogen, Novartis, and Alexion. T.Z. reports scientific advisory board and/or consulting for Biogen, Roche, Neuraxpharm, Novartis, BMS, Sanofi, and Merck; compensation for serving on speakers bureaus for Roche, Neuraxpharm, Novartis, Merck, Novo Nordisk, Sanofi, BMS, TEVA, and Biogen; and research support from Biogen, Novartis, Merck, TEVA, and Sanofi.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee at Technische Universität Dresden (approval number BO-EK-320062021).
: Informed consent was obtained from all individual participants included in the study.
